Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10577.14 | 1.0410 | 1.0845 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10577.14 | 0.9807 | 0.9603 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10577.14 | 0.9981 | 0.9960 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10577.14 | 0.9342 | 0.8649 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10577.14 | 0.9385 | 0.8736 | 0.9722 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10578.14 | 0.9627 | 0.9551 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10578.14 | 1.0001 | 1.0001 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10578.14 | 0.9630 | 0.9554 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10578.14 | 0.9612 | 0.9533 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10578.14 | 0.9772 | 0.9726 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10578.14 | 1.0002 | 1.0002 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10578.14 | 0.9216 | 0.9047 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10578.14 | 0.9446 | 0.9330 | 1.6718 | |
| HCC38 | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10578.14 | 0.8537 | 0.8195 | 1.6718 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10519.14 | 0.9847 | 0.9702 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10519.14 | 0.9911 | 0.9826 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10519.14 | 0.9895 | 0.9795 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10519.14 | 1.0056 | 1.0110 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10519.14 | 1.0306 | 1.0595 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10519.14 | 0.9832 | 0.9672 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10519.14 | 1.0216 | 1.0421 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10519.14 | 0.9447 | 0.8923 | 1.0269 | |
| MDA-MB-134-VI | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10519.14 | 0.9404 | 0.8839 | 1.0269 | |
| MDA-MB-175-VII | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10642.14 | 0.9027 | 0.6589 | 0.5473 | |
| MDA-MB-175-VII | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10642.14 | 0.9141 | 0.6974 | 0.5473 |